Document Detail

Platinum-based chemotherapy in triple-negative breast cancer.
MedLine Citation:
PMID:  18567607     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Experimental data suggest that triple-negative (TN) breast cancer may have increased sensitivity to platinum-based chemotherapy but clinical data are limited. We present our long-term results with platinum-based chemotherapy for TN breast cancer. PATIENTS AND METHODS: In all, 94 (17 TN), 79 (11 TN) and 155 (34 TN) patients receiving platinum-based chemotherapy in neo-adjuvant/adjuvant and advanced setting were included. Response rates and outcome were compared for TN tumours versus others. RESULTS: Neo-adjuvant complete response rates were significantly higher for TN tumours (88%) than others (51%; P = 0.005). The 5-year overall survival (OS) for TN tumours following adjuvant/neo-adjuvant chemotherapy was 64% [95% confidence interval (CI) 44% to 79%] compared with 85% (95% CI 79% to 90%) for others. Five-year disease-free survival for TN tumours was 57% (95% CI 37% to 73%) compared with 72% (95% CI 64% to 78%) for others. For patients with advanced breast cancer, overall response rates were 41% for TN tumours and 31% for others (P = 0.3). Patients with TN tumours had a significantly prolonged progression-free survival of 6 months compared with 4 months for others (P = 0.05), though the OS was not significantly different between the two groups (11 versus 7 months). CONCLUSION: Platinum-based chemotherapy achieves increased response rates for TN tumours, with a trend towards worse survival in early breast cancer through an improved survival in advanced disease. Prospective randomised trials are warranted.
B Sirohi; M Arnedos; S Popat; S Ashley; A Nerurkar; G Walsh; S Johnston; I E Smith
Related Documents :
2580757 - The effectiveness of multidrug treatment by bleomycin, methotrexate, and cis-platinum i...
12402727 - Epidural analgesia and backache: a randomized controlled comparison with intramuscular ...
19942597 - Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a ...
15541827 - Carcinoma in situ from the view of complete resection.
10492627 - Chemotherapy for operable gastric cancer: results of the dutch randomised famtx trial. ...
9835247 - Response rate in patient satisfaction research: an analysis of 210 published studies.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-06-20
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  19     ISSN:  1569-8041     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-10-27     Completed Date:  2008-11-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1847-52     Citation Subset:  IM    
Breast Unit, Royal Marsden NHS Foundation Trust, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*,  pathology
Carboplatin / administration & dosage
Chemotherapy, Adjuvant
Cisplatin / administration & dosage
Disease-Free Survival
Epirubicin / administration & dosage
Fluorouracil / administration & dosage
Middle Aged
Mitomycin / administration & dosage
Neoadjuvant Therapy
Neoplasm Metastasis
Neoplasm Recurrence, Local / pathology
Neoplasm Staging
Vinblastine / administration & dosage
Reg. No./Substance:
15663-27-1/Cisplatin; 41575-94-4/Carboplatin; 50-07-7/Mitomycin; 51-21-8/Fluorouracil; 56420-45-2/Epirubicin; 865-21-4/Vinblastine
Comment In:
Ann Oncol. 2008 Nov;19(11):1975-6   [PMID:  18765461 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Estimation of benchmark dose for bone damage and renal dysfunction in a Chinese male population occu...
Next Document:  Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of...